No Data
Oriental Biotech: 2024 Annual Results Pre-loss Announcement
2024 Annual Results Advance Loss Announcement
January 17 A-shares investment warning highlights︱ *ST Baoxin: Received a preliminary notice of the proposed termination of the company’s Stocks listing; LONGi Green Energy Technology: Expected loss of 8.2 billion yuan to 8.8 billion yuan for the year 202
Zhejiang Orient Gene Biotech: Expected loss of 0.485 billion yuan to 0.535 billion yuan for the year 2024.
Zhejiang Orient Gene Biotech (688298.SH): A forecasted loss of 0.485 billion yuan to 0.535 billion yuan for the year 2024.
On January 16, Gelonghui reported that Zhejiang Orient Gene Biotech (688298.SH) announced a pre-loss statement for the annual performance of 2024. According to preliminary calculations by the financial department, it is expected that the net income attributable to the shareholders of the parent company for the year 2024 will show a loss compared to the previous year (statutory disclosure data -0.398 billion yuan), anticipated to be between -0.485 billion yuan and -0.535 billion yuan. The net income attributable to the shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between -0.55 billion yuan and -0.595 billion yuan.
Private Companies Among Zhejiang Orient Gene Biotech Co., Ltd's (SHSE:688298) Largest Stockholders and Were Hit After Last Week's 7.8% Price Drop
Chinese Stocks Plunge as Manufacturing Slowdown Dampens Sentiment; Huafu Fashion Down 4%
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Using Debt Sensibly?